Moderna shares double after experimental mRNA cancer treatment passes key test
Moderna shares surged more than double on Wednesday following positive results from a study of an experimental mRNA cancer treatment. The innovative therapy, called intismeran, is being co-developed by Moderna and Merck. Unlike traditional cancer vaccines, intismeran is tailored to each patient's unique tumor mutations. In ongoing trials, the combined treatment of intismeran with Merck's Keytruda immunotherapy showed significantly better outcomes compared to Keytruda alone in melanoma patients.
The experimental combination resulted in extended survival rates without cancer recurrence or metastasis.
Written by urgent.news from Gulf News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Moderna and Merck shares soar on mRNA cancer vaccine axios.com
- Moderna praised by Wall Street for the promised effectiveness of a treatment using messenger RNA against skin cancer lemonde.fr
- Moderna, Merck mRNA melanoma vaccine succeeds in first late-stage cancer trial ynetnews.com
- How Moderna's melanoma mRNA vaccine could fight deadliest skin cancer cbsnews.com
- Moderna, Merck breakthrough could usher in wave of cancer vaccines japantimes.co.jp
- Promising Results for mRNA Cancer Vaccine from Moderna and Merck time.com
- Biotechs hit a post-pandemic high after mRNA trial win for Moderna, Merck seekingalpha.com
